The effect of dapagliflozin in patients with type 2 diabetes mellitus in combination with hypertension and obesity

Abstract

The objective : to determine the effect of 6 months therapy with a new class of glucose lowering drugs – a sodium glucose cotransporter type 2 inhibitor dapagliflozin on glycemic control, body weight, blood pressure in patients with diabetes mellitus 2 type in combination with essential hypertension and obesity. Patients and methods . The 36 patients with type 2 diabetes mellitus, hypertension and obesity were examined. Dapagliflozin in the dose of 10 mg was used in the complex therapy Results . The results of the study showed that drugs in a combination therapy provided the glycemic control, led to the decrease of body mass index by 7,6% (р<0,05), that proves its advantage in the presence of overweight or obesity. The use of the drug has not led to the correction of lipid imbalances. Conclusion .The results of the daily blood pressure monitoring indicate that dapagliflozin has antihypertensive activity, that confirms the reasonability of its use in patients with type 2 diabetes mellitus in combination with essential hypertension and obesity.